Ulevostinag

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameUlevostinag
Drug Alias NameMK-1454
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionStimulator of interferon genes stimulants
TargetsStimulator of interferon genes
Therapy Area/IndicationsSolid tumoursSquamous Cell Carcinoma of Head and NeckLymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNorwayAustralia +[10] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesMerck & Co IncMerck Sharp & Dohme Corp
China Registration ClassN/A

Develop Information

Active CompaniesMerck Sharp & Dohme LLC
Inactive CompaniesN/A
Active IndicationsSolid tumoursSquamous Cell Carcinoma of Head and NeckLymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksDrugBank